We are live on ! Find out more
Mitsubishi UFJ Asset Management

Mitsubishi UFJ Asset Management Portfolio holdings

AUM $180B
1-Year Est. Return 37.51%
This Fund
S&P 500
This Quarter Est. Return
+11.76%
1 Year Est. Return
+37.51%
3 Year Est. Return
+115.4%
5 Year Est. Return
+142.39%
10 Year Est. Return
+552.78%
AUM
$56.8B
AUM Growth
+$7.38B
Cap. Flow
+$2.67B
Cap. Flow %
4.7%
Top 10 Hldgs %
27.76%
Holding
1,604
New
60
Increased
723
Reduced
255
Closed
38

Sector Composition

Rank Sector Weight
1 Technology 29.05%
2 Healthcare 15.55%
3 Financials 13.4%
4 Consumer Discretionary 8.71%
5 Consumer Staples 7.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MARA icon
976
Marathon Digital Holdings
MARA
$3.56B
$282K ﹤0.01%
12,038
-7,494
-38% -$94.6K
KRYS icon
977
Krystal Biotech
KRYS
$9.72B
$279K ﹤0.01%
2,345
-662
-22% -$73.4K
ARWR icon
978
Arrowhead Research
ARWR
$12.1B
$279K ﹤0.01%
8,714
+952
+12% +$25.3K
XNCR icon
979
Xencor
XNCR
$1.71B
$278K ﹤0.01%
12,725
+2,378
+23% +$45.2K
KEEL
980
Keel Infrastructure Corp
KEEL
$2.04B
$278K ﹤0.01%
98,880
+509
+0.5% +$818
BNTX icon
981
BioNTech
BNTX
$23.1B
$274K ﹤0.01%
2,487
-238
-9% -$24K
LAND
982
Gladstone Land Corp
LAND
$358M
$273K ﹤0.01%
19,400
NVS icon
983
Novartis
NVS
$288B
$270K ﹤0.01%
2,580
+585
+29% +$56.5K
ALX
984
Alexander's
ALX
$1.4B
$260K ﹤0.01%
1,205
VERV
985
DELISTED
Verve Therapeutics
VERV
$258K ﹤0.01%
19,884
+3,405
+21% +$42.2K
VIR icon
986
Vir Biotechnology
VIR
$1.52B
$253K ﹤0.01%
25,078
+14,271
+132% +$130K
RXRX icon
987
Recursion Pharmaceuticals
RXRX
$1.78B
$252K ﹤0.01%
26,055
-6,947
-21% -$49.5K
DNA icon
988
Ginkgo Bioworks
DNA
$488M
$247K ﹤0.01%
4,016
-1,610
-29% -$98.6K
RKT icon
989
Rocket Companies
RKT
$42.6B
$243K ﹤0.01%
18,213
-3,300
-15% -$31.6K
NTLA icon
990
Intellia Therapeutics
NTLA
$1.66B
$242K ﹤0.01%
8,204
+1,553
+23% +$44.6K
HAPN
991
Happen Inc
HAPN
$2.27B
$235K ﹤0.01%
27,761
+9,184
+49% +$57.7K
FSR
992
DELISTED
Fisker Inc.
FSR
$235K ﹤0.01%
157,661
+49,234
+45% +$174K
IBN icon
993
ICICI Bank
IBN
$106B
$233K ﹤0.01%
9,800
-2,140
-18% -$49.3K
BBIO icon
994
BridgeBio Pharma
BBIO
$15.9B
$231K ﹤0.01%
6,113
-9,176
-60% -$276K
CRBU icon
995
Caribou Biosciences
CRBU
$160M
$230K ﹤0.01%
+44,202
New +$219K
HUT
996
Hut 8
HUT
$10.2B
$227K ﹤0.01%
18,433
-180
-1% -$1.92K
ABCL icon
997
AbCellera Biologics
ABCL
$3.36B
$221K ﹤0.01%
38,855
+4,641
+14% +$21.5K
ROIV icon
998
Roivant Sciences
ROIV
$26.2B
$221K ﹤0.01%
20,311
-1,139
-5% -$11.1K
OPI
999
DELISTED
Office Properties Income Trust
OPI
$218K ﹤0.01%
31,375
+4,950
+19% +$26.3K
CRSP icon
1000
CRISPR Therapeutics
CRSP
$5.22B
$218K ﹤0.01%
3,481
-1,003
-22% -$55.4K

Similar funds

Mitsubishi UFJ Asset Management's Q4 2023 Portfolio in Review

As of Q4 2023, Mitsubishi UFJ Asset Management held 1,604 positions worth $56.8B, up 15% from $49.4B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Mitsubishi UFJ Asset Management deployed $2.67B of net new capital in Q4 2023, opening 60 new positions and adding to 723 existing holdings. Its largest new stake was Veralto: 984,212 shares worth $76.8M.

By sector, the portfolio is most concentrated in Technology at 29% of assets, up from 29% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was PayPal, an estimated $218M trimmed.

  • Mitsubishi UFJ Asset Management's largest Q4 2023 buy was Veralto: 984,212 shares worth $76.8M.
  • Mitsubishi UFJ Asset Management added most to Procter & Gamble in Q4 2023, an estimated $205M increase.
  • Mitsubishi UFJ Asset Management's biggest Q4 2023 reduction was PayPal, cutting an estimated $218M.
  • Mitsubishi UFJ Asset Management fully exited Activision Blizzard in Q4 2023, selling an estimated $64M.
  • Mitsubishi UFJ Asset Management's ten largest holdings make up 28% of its $56.8B portfolio in Q4 2023.
  • Mitsubishi UFJ Asset Management opened 60 new positions and closed 38 in Q4 2023.
  • Mitsubishi UFJ Asset Management's portfolio value rose 15% quarter-over-quarter to $56.8B.

Based on Mitsubishi UFJ Asset Management's 13F filing for Q4 2023, filed 8 Feb 2024.